[Chinese Guideline for the Diagnosis and Treatment of Adult Autoimmune Hemolytic Anemia (2023)]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2023 Mar 29

PMID 36987718

Affiliations

Soon will be listed here.

Citing Articles

[Chinese expert consensus on the diagnosis and treatment of Evans syndrome (2024)].

Zhonghua Xue Ye Xue Za Zhi. 2024; 45(9):809-815.

PMID: 39414602 PMC: 11518912. DOI: 10.3760/cma.j.cn121090-20240506-00171.

References

Fattizzo B, Michel M, Zaninoni A, Giannotta J, Guillet S, Frederiksen H . Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study. Haematologica. 2020; 106(2):622-625. PMC: 7849557. DOI: 10.3324/haematol.2020.250522. View

Berentsen S, Ulvestad E, Gjertsen B, Hjorth-Hansen H, Langholm R, Knutsen H . Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004; 103(8):2925-8. DOI: 10.1182/blood-2003-10-3597. View

Xing L, Zhao M, Wang Y, Feng Y, Qu Y, Duan N . Characteristics of patients with autoimmune haemolytic anaemia secondary to lymphoproliferative disorder: A single-centre retrospective analysis. Sci Rep. 2019; 9(1):19716. PMC: 6928151. DOI: 10.1038/s41598-019-56162-y. View

Jalink M, Berentsen S, Castillo J, Treon S, Cruijsen M, Fattizzo B . Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood. 2021; 138(20):2002-2005. DOI: 10.1182/blood.2021012039. View

Fu R, Yan S, Wang X, Wang G, Qu W, Wang H . A monocentric retrospective study comparing pulse cyclophosphamide therapy versus low dose rituximab in the treatment of refractory autoimmune hemolytic anemia in adults. Int J Hematol. 2016; 104(4):462-7. DOI: 10.1007/s12185-016-2056-5. View

Jager U, Barcellini W, Broome C, Gertz M, Hill A, Hill Q . Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev. 2019; 41:100648. DOI: 10.1016/j.blre.2019.100648. View

Lechner K, Jager U . How I treat autoimmune hemolytic anemias in adults. Blood. 2010; 116(11):1831-8. DOI: 10.1182/blood-2010-03-259325. View

Lam L, Murphy S, Kokkinaki D, Venosa A, Sherrill-Mix S, Casu C . DNA binding to TLR9 expressed by red blood cells promotes innate immune activation and anemia. Sci Transl Med. 2021; 13(616):eabj1008. PMC: 9065924. DOI: 10.1126/scitranslmed.abj1008. View

Birgens H, Frederiksen H, Hasselbalch H, Rasmussen I, Nielsen O, Kjeldsen L . A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013; 163(3):393-9. DOI: 10.1111/bjh.12541. View

10.

Barcellini W, Fattizzo B . How I treat warm autoimmune hemolytic anemia. Blood. 2021; 137(10):1283-1294. DOI: 10.1182/blood.2019003808. View

11.

Montillo M, OBrien S, Tedeschi A, Byrd J, Dearden C, Gill D . Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study. Blood Cancer J. 2017; 7(2):e524. PMC: 5386339. DOI: 10.1038/bcj.2017.5. View

12.

Fattizzo B, Zaninoni A, Pettine L, Cavallaro F, Di Bona E, Barcellini W . Low-dose rituximab in autoimmune hemolytic anemia: 10 years after. Blood. 2019; 133(9):996-998. DOI: 10.1182/blood-2018-12-885228. View

13.

Yusuf H, Hooper W, Grosse S, Parker C, Boulet S, Ortel T . Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees. Thromb Res. 2014; 135(1):50-7. PMC: 4480419. DOI: 10.1016/j.thromres.2014.10.012. View

14.

Barcellini W, Zaja F, Zaninoni A, Imperiali F, Battista M, Di Bona E . Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood. 2012; 119(16):3691-7. DOI: 10.1182/blood-2011-06-363556. View

15.

Hill Q, Stamps R, Massey E, Grainger J, Provan D, Hill A . The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol. 2016; 176(3):395-411. DOI: 10.1111/bjh.14478. View

16.

Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet A . Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. Autoimmun Rev. 2014; 14(4):304-13. DOI: 10.1016/j.autrev.2014.11.014. View

17.

Berentsen S . How I treat cold agglutinin disease. Blood. 2021; 137(10):1295-1303. DOI: 10.1182/blood.2019003809. View

18.

Roth A, Barcellini W, DSa S, Miyakawa Y, Broome C, Michel M . Sutimlimab in Cold Agglutinin Disease. N Engl J Med. 2021; 384(14):1323-1334. DOI: 10.1056/NEJMoa2027760. View

19.

Bussone G, Ribeiro E, Dechartres A, Viallard J, Bonnotte B, Fain O . Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases. Am J Hematol. 2009; 84(3):153-7. DOI: 10.1002/ajh.21341. View

20.

Liu H, Shao Z, Cui Z, Wu Y, Qin T, Fu R . [An analysis of relapse and risk factors of autoimmune hemolytic anemia and Evans syndrome]. Zhonghua Xue Ye Xue Za Zhi. 2003; 24(10):534-7. View